IP THERAPY WITH CISPLATIN OR CARBOPLATIN AND FLOXURIDINE FOR OVARIAN & GI CANCER

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a single-site, phase I/II study of intraperitoneal (IP) therapy with cisplatin or carboplatin and floxuridine (FUdR) as consolidation for ovarian and gastrointestinal malignancies. The protocol arises from observations over the last 10-12 years that IP treatment of patients with ovarian cancer achieved improved loco-regional control of recurrent disease. Preliminary work by the PI at USC and at NYU validates this approach. The primary objective of the study is to assess the toxicity, tolerance and completion rate of an IP drug regimen consisting of platinum and FUdR for gynecologic or GI malignancies with minimal residual disease confined to the peritoneum. A secondary objective is to determine the sites of failure and to estimate the time to failure and survival time following such an IP regimen. The protocol also has as one of its goals the determination of prognostic factors for disease progression and laparoscopic inspection of the peritoneum to determine the extent of residual disease prior to initiation of treatment. Patients with positive CA-125 will be followed for the response of that marker. Patients who develop neuro or renal toxicity will be switched from cisplatin to carboplatin as appropriate.